Skip to content
Checking whether you are signed in

Merck & Co., Inc.

MRKNew York Stock ExchangeFull coverage

Price
Loading your watchlists

AI-generatedPublished Nov 1, 2026, 11:59 PM UTC

Q3 fiscal 2026 edition

A free account unlocks one dossier edition a month.

Create a free account

Already have an account? Sign in

Summary

Free to read

Merck & Co. sells prescription medicines, vaccines and animal-health products, and its cancer drug KEYTRUDA made about half of 2025 sales before its main US patent ends in 2028 and Medicare price setting begins in 2029. In the third quarter of 2026 sales rose 4.7%, but most of that came from the timing of purchases, while new products, including the injectable KEYTRUDA QLEX, rose to 13.6% of sales from 5.1% a year earlier. Merck spent about $26.4 billion on three acquisitions to build the replacement, and its reported earnings this year are cut by large deal charges. Moatsight estimates revenue of about $68.7 billion over the next four quarters, with the outcome resting on how fast the new products grow and what Merck pays for the next ones.

In the full dossier

  1. Part 1In brief
  2. Part 2Business explainer
  3. Part 3Earnings
  4. Part 4Valuation and projections
  5. Part 5What changed

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers